SNAP-8: Reproducing a Toxin Mechanism Without the Toxin
An octapeptide modelled on SNAP-25, designed to compete for a place in the SNARE complex rather than cleave it.
SNAP-8 exists because of a specific engineering question: could the mechanism behind botulinum toxin be reproduced by something that is not a toxin? It is an eight-residue peptide designed to interfere with the same protein complex, and the research around it is best read as protein-interaction work rather than as cosmetics.
Everything below describes published preclinical and in-vitro research. It is not a therapeutic claim, not medical advice, and not a statement about effects in humans.
What it is
SNAP-8 is an octapeptide, an extended analogue of the hexapeptide Argireline (acetyl hexapeptide-3), with a molecular weight of about 1075 Da. Both are modelled on the N-terminal end of SNAP-25.
SNAP-25 is one of three proteins that form the SNARE complex, the machinery that docks a vesicle to a membrane so its contents can be released. Botulinum toxin type A works by cleaving SNAP-25, which stops the complex assembling. SNAP-8 is designed to compete with SNAP-25 for a position in that complex rather than to cut anything — the same target approached from the opposite direction.
Reported mechanism
- SNARE complex competition — the central claim in the literature: the peptide mimics the N-terminal domain of SNAP-25 and competes for incorporation, producing a less efficient complex.
- Neurotransmitter release models — in-vitro work measuring catecholamine release from chromaffin cells, the standard system for this kind of question.
- Topical formulation studies — a body of work on skin penetration, since an eight-residue hydrophilic peptide does not cross the stratum corneum easily and formulation is the limiting factor.
Practical notes
| Length | 8 amino acids |
|---|---|
| Molecular weight | ~1075 Da |
| Modelled on | N-terminal domain of SNAP-25 |
| Related compound | Argireline (acetyl hexapeptide-3) |
| Typical vial size | 10 mg |
Worth noting for study design: much of the published work uses concentrations in cell culture that formulation studies suggest are difficult to reach through intact skin. Reading the in-vitro literature and the topical literature as one body of evidence is a common error.
Reading this literature critically
- SNAP-8 is not an approved medicine in the European Union. It appears in cosmetic formulation, which is a separate regulatory category from what is supplied here.
- A significant portion of the published work comes from or is funded by ingredient manufacturers, which is normal in this field and still worth weighing.
- The comparison to botulinum toxin is mechanistic — same complex — and not a statement about comparable potency. The toxin is enzymatic and catalytic; a competing peptide is neither.
- Penetration is the recurring limitation, and studies that do not address it are measuring something other than what a topical application would produce.
Handling
Supplied as lyophilised powder at 10 mg. Stable at room temperature as a powder, refrigerated after reconstitution. Our reconstitution guide covers technique and the calculator the arithmetic.
Every batch is analysed by an independent laboratory for HPLC purity and mass-spectrometric identity, with batch-matched certificates available on request. See the SNAP-8 10mg product page, or the rest of longevity research.
All products and information referenced are for in-vitro research and laboratory use only. Nothing here is medical advice, and no therapeutic claim is made or implied.